四环医药的亏损还在继续。本周,四环医药发布公告,2024年预计实现收入不低于18亿元,亏损不超过6亿元,相较于2023年约5400万元的亏损明显扩大,也成为四环医药继2022年之后连续第三年亏损。仿制药业务持续走低等成为亏损的重要原因,虽然公司医美业务连续增长,去年预增不低于50%,但依然挽救不了四环医药的整体业绩。仿制药业务走低连续三年亏损据四环医药公告,公司2024年预计实现收入不低于18亿元...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.